Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, has scheduled its Q2 2025 earnings conference call for August 1, 2025, at 8:30 a.m. ET. The company will release its financial results before the market opens on the same day.
Investors can access the call via U.S. dial-in (800-715-9871) or international dial-in (646-307-1963) using conference ID 9627149. A webcast will be available on Ocugen's investor relations website, with a replay accessible for approximately 45 days after the event.
Ocugen (NASDAQ: OCGN), un'azienda biotecnologica specializzata in terapie geniche per malattie della cecità, ha programmato la sua conference call sui risultati del secondo trimestre 2025 per il 1° agosto 2025 alle 8:30 ET. La società pubblicherà i risultati finanziari prima dell'apertura del mercato lo stesso giorno.
Gli investitori potranno partecipare alla chiamata tramite numero statunitense (800-715-9871) o internazionale (646-307-1963) utilizzando l'ID conferenza 9627149. Sarà disponibile anche una trasmissione in streaming sul sito web delle relazioni con gli investitori di Ocugen, con la possibilità di riascoltare la registrazione per circa 45 giorni dopo l'evento.
Ocugen (NASDAQ: OCGN), una empresa biotecnológica enfocada en terapias génicas para enfermedades de la ceguera, ha programado su conferencia telefónica de resultados del segundo trimestre de 2025 para el 1 de agosto de 2025 a las 8:30 a.m. ET. La compañía publicará sus resultados financieros antes de la apertura del mercado ese mismo día.
Los inversionistas pueden acceder a la llamada mediante el número de EE.UU. (800-715-9871) o número internacional (646-307-1963) usando el ID de conferencia 9627149. Habrá una transmisión en vivo disponible en el sitio web de relaciones con inversionistas de Ocugen, con una repetición accesible durante aproximadamente 45 días después del evento.
Ocugen (NASDAQ: OCGN)은 실명 질환을 위한 유전자 치료제에 집중하는 생명공학 회사로, 2025년 8월 1일 오전 8시 30분(동부시간)에 2025년 2분기 실적 컨퍼런스 콜을 예정하고 있습니다. 회사는 같은 날 시장 개장 전에 재무 결과를 발표할 예정입니다.
투자자들은 미국 내 전화 접속 번호(800-715-9871) 또는 국제 전화 번호(646-307-1963)를 통해 컨퍼런스 ID 9627149를 사용하여 전화에 참여할 수 있습니다. Ocugen 투자자 관계 웹사이트에서 웹캐스트가 제공되며, 이벤트 후 약 45일간 다시 듣기 서비스가 가능합니다.
Ocugen (NASDAQ : OCGN), une société de biotechnologie spécialisée dans les thérapies géniques pour les maladies de la cécité, a programmé sa conférence téléphonique sur les résultats du deuxième trimestre 2025 le 1er août 2025 à 8h30 (heure de l'Est). L'entreprise publiera ses résultats financiers avant l'ouverture des marchés ce même jour.
Les investisseurs peuvent accéder à l'appel via un numéro américain (800-715-9871) ou international (646-307-1963) en utilisant l'ID de conférence 9627149. Un webcast sera disponible sur le site des relations investisseurs d'Ocugen, avec une rediffusion accessible pendant environ 45 jours après l'événement.
Ocugen (NASDAQ: OCGN), ein Biotechnologieunternehmen, das sich auf Gentherapien für Erblindungskrankheiten spezialisiert hat, hat seine Telefonkonferenz zu den Quartalsergebnissen Q2 2025 für den 1. August 2025 um 8:30 Uhr ET angesetzt. Das Unternehmen wird seine Finanzergebnisse am selben Tag vor Markteröffnung veröffentlichen.
Investoren können über eine US-Einwahlnummer (800-715-9871) oder eine internationale Einwahlnummer (646-307-1963) mit der Konferenz-ID 9627149 an der Telefonkonferenz teilnehmen. Ein Webcast wird auf der Investor-Relations-Webseite von Ocugen verfügbar sein, mit einer Wiedergabe, die etwa 45 Tage nach der Veranstaltung abrufbar ist.
- None.
- None.
MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025.
Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 9627149
Webcast: Available on the events section of the Ocugen investor site
A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When will Ocugen (NASDAQ: OCGN) report Q2 2025 earnings?
How can investors access Ocugen's Q2 2025 earnings call?
What is Ocugen's main business focus?
How long will Ocugen's Q2 2025 earnings call replay be available?
